Neurotrophic factors (NTFs) are known to govern the processes involved in central nervous system cell proliferation and differentiation. Thus, they represent very attractive candidates for use in the study and therapy of neurological disorders. We constructed recombinant herpesvirus-basedvectors capable of expressing fibroblast growth factor-2 (FGF-2) and ciliary neurotrophic factor (CNTF) alone or in combinations. In vitro, vectors expressing FGF-2 and CNTF together, but not those expressing either NTF alone, caused proliferation of O-2A progenitors. Furthermore, based on double-labeling experiments performed using markers for neurons (MAP-2), oligodendrocytes (CNPase) and astrocytes (GFAP), most of the new cells were identified as astrocytes, but many expressed neuronal or oligodendrocytic markers. In vivo, vectors have been injected in the rat hippocampus. At 1 month after inoculation, a highly significant increase in BrdU-positive cells was observed in the dentate gyrus of animals injected with the vector expressing FGF-2 and CNTF together, but not in those injected with vectors expressing the single NTFs. Furthermore, double-labeling experiments confirmed in vitro data, that is, most of the new cells identified as astrocytes, some as neurons or oligodendrocytes. These data show the feasibility of the vector approach to induce proliferation and differentiation of neurons and/or oligodendrocytes in vivo. Gene Therapy (2005) 12, 559-569.
Introduction
For long, it has been believed that neurons could not replicate in the adult central nervous system (CNS) and, thus, that the brain is incapable of self-repair. 1 This dogma has been recently shattered, 2 and it is now clear that multipotent neural stem cells (NSCs) and progenitors with more limited capacities of differentiation are present in many adult brain areas, ensuring continuous generation of new neurons. 3 Importantly, these activities are modulated under physiological and pathological conditions. 2, 4 Thus far, efforts towards the treatment of neurological disorders caused by or associated with neurodegeneration have mainly focused at preventing cell death. 1 However, the above observations suggest an alternative approach: to recruit endogenous NSCs or precursors for generating new neurons. The discovery of gene products involved in neuron differentiation and brain repair, and the availability of new tools and techniques, provide strategies to challenge the value of this new approach.
Among the genes involved in neuron differentiation and repair, the neurotrophic factors (NTFs) have attracted particular interest.
The biological properties of NTFs led to the suggestion that they may be used for the treatment of degenerative neurological diseases, such as Parkinson's, Alzheimer's, amyotrophic lateral sclerosis, or associated with cell damage, such as some forms of epilepsy. 5 To date, however, attempts to develop clinical treatments have not been successful. Multiple explanations may be put forward to interpret these unsatisfactory results, including the poor transfer of NTFs to the CNS when peripherally administered, the side effects, the lack of anatomical specificity and the fact that single NTFs have been employed in all studies, 5 while synergic effects between NTFs have been demonstrated, [6] [7] [8] suggesting that combinations of NTFs are more likely to be successful. It is now thought that the best results will be obtained only if achieving localized, regulated expression of NTFs. 5 A promising means for obtaining this goal is the use of viral vectors engineered to express NTFs.
The aim of the present study was to challenge this idea by attempting to augment the regenerative capacity of hippocampal NSCs and/or progenitors. The hippocampus has been chosen because it is extremely susceptible to cell damage induced by seizures or ischemia. 9, 10 Under physiological conditions, the production of new neurons is very limited in this brain region, essentially restricted to a population of cells in the subgranular layer of the dentate gyrus. 11 However, administration of NTFs has been reported to stimulate progenitors located in the periventricular region and in the parenchyma to replace CA1 neurons damaged by ischemia. 7 To pursue our proposal, we have employed replication-deficient herpes simplex virus-1 (HSV-1)-based vectors engineered to express NTFs. We chose these vectors for the following reasons: 12 (a) HSV-1 has appropriate biological characteristics for gene transfer in the brain: intrinsic neurotropism, capacity to infect nondividing cells; (b) at variance with other viral vectors, HSV vectors are capable of incorporating large and/or multiple transgenes, 13 making it possible to express in the very same cell the multiple genes necessary to induce differentiation of a specific cell lineage (this feature is of particular interest, in view of the synergies between NTFs). Furthermore, at variance with a pharmacological approach, 7 (c) they ensure a sufficiently prolonged production of NTF without the need to implant chronic devices; and (d) they allow to evaluate intracrine effects, which may be relevant for NTFs that do not appear to be secreted under normal conditions. Of course, this approach has limitations. For example, it remains difficult to obtain prolonged transgene expression. 14, 15 In the frame of this study, however, these issues are not very relevant, because the pathological situation under study requires transient expression of NTFs, and not lifelong replacement.
We decided to begin by studying a combination of NTFs with established synergic actions on NSC differentiation: fibroblast growth factor-2 (FGF-2)-and ciliaryderived neurotrophic factor (CNTF). Most NSC maintain an undifferentiated state and the capacity to self-renew in response to FGF-2. 3 In vitro, however, depending on the concentrations of this NTF, it is also possible to generate neurons 16 or oligodendrocytes, 17 and FGF-2 can specify a glial fate. 18 In contrast, CNTF acts as a differentiation factor for glia cells. 19, 20 Accordingly, FGF-2 and CNTF have been reported to synergistically control the proliferation of NSC and their terminal differentiation in astrocytes. 8, 18, 21 Under specific experimental conditions, however, the combination of FGF-2 and CNTF has also been reported to promote oligodendroglial or neuronal differentiation. [22] [23] [24] [25] [26] [27] Thus, it was expected that vectors expressing FGF-2 and CNTF would mimic this effect both in vitro and in the adult brain. Indeed, this proved to be the case.
Part of this study has been previously presented in abstract form. 28 
Results

Vectors
A schematic representation of the vectors employed in this study is shown in Figure 1 . All these vectors are triple mutants, defective for the ICP4, ICP27 and ICP22 immediate-early genes. They ensure efficient expression of the transgene. 14, 15, 29 Although this mutant background contains some degree of residual toxicity for some cell types, 15 this phenomenon does not appear to be longlasting nor to heavily affect neurons. 14 For FGF-2, we used a previously characterized vector, TH-FGF2, 30 in which the transgene was introduced into the thymidine kinase (tk) (UL23) locus of the control (TH-lacZ) vector by digestion of the viral DNA and by homologous recombination with an expression cassette containing sequences coding for FGF-2 under the control of the human cytomegalovirus immediate-early (HCMV IE) promoter. For CNTF, we used a vector, T0-CNTF/green fluorescence protein (GFP), in which the transgene was introduced into the UL41 locus of another control vector (T0-lacZ/GFP) by digestion of the viral DNA and by homologous recombination with an expression cassette containing sequences coding for CNTF under the control of the ICP0 promoter.
FGF-2 has been reported to regulate the competence of progenitors to respond to CNTF: in fact, cortical cells exposed to FGF-2 and CNTF together or sequentially (but not cells exposed to FGF-2 alone or to CNTF alone) differentiate into astrocytes. 8 Therefore, we chose two distinct promoters, in an attempt to mimic this 'sequential' activation of FGF-2 and CNTF. The HCMV IE promoter (driving FGF-2 in our system) is known to ensure robust, but very transient, transgene expression, 30 while the ICP0 promoter (driving CNTF) provides a longer-lasting expression.
14 The double mutant (TH-FGF2/0-CNTF/GFP) was obtained by crossing over TH-FGF2 and T0-CNTF/GFP. TH-lacZ and T0-lacZ/ GFP were used as controls.
Transgene expression in vitro
The purity of the vectors used in this study was verified by measuring the amount of FGF-2 and CNTF present in À , ICP27 À ) containing the rat lacZ gene in the UL23 (tk) locus, driven by the HCMV IE promoter. (b) and (c) Graphic maps of the viruses TH-FGF2 and T0-CNTF/GFP, triple mutants containing the rat FGF-2 or CNTF cDNA in the UL23 and UL41 loci, respectively. T0-CNTF/GFP also contains the GFP gene in the ICP22 locus. The CNTF gene is driven by the ICP0 IE promoter; the FGF-2 and the GFP genes are driven by the HCMV IE promoter. (d) Graphic map of the virus TH-FGF2/ 0-CNTF/GFP, a triple mutant containing the rat FGF-2 gene in the tk locus, the rat CNTF gene in the UL41 locus, and the GFP cDNA in the ICP22 locus. The FGF-2 and GFP genes are driven by the HCMV IE promoter; the CNTF gene is driven by ICP0 IE promoter.
HSV vector-expressed neurotrophic factors P Marconi et al each viral stock. No measurable amount of either NTF was found on the purified stocks, based on an ELISA assay, indicating the absence of contaminating proteins (data not shown).
To evaluate whether cells infected with the recombinant viruses could express the corresponding NTFs and to quantify the transgene levels, ELISA assays were performed on total proteins extracted from Vero cell monolayers infected with the different vectors at a multiplicity of infection (MOI) of 1.0. Vero cells were infected with TH-FGF2, T0-CNTF/GFP, TH-FGF2/0-CNTF/GFP or with the control viruses (TH-lacZ and T0-lacZ/GFP), and FGF-2 or CNTF expression was determined at different time-points postinfection (1-4 days). In cells infected with either NTF vector, we observed a robust expression of the transgene up to 4 days, whereas in cells infected with the control (lacZ) vectors the expression of NTFs was virtually absent (Figure 2 ). These data have been confirmed in a Western blot analysis (data not shown).
Biological activity in vitro
To determine the biological activity of the NTF proteins expressed by the transduced cells and, further, to determine if the combination of FGF-2 and CNTF exerted different effects compared with either NTF alone, we infected O-2A progenitor cells with TH-FGF2, T0-CNTF/ GFP, TH-FGF2/0-CNTF/GFP or with the control vector, TH-lacZ. O-2A cells were described as oligodendrocytetype 2 astrocyte (hence O-2A) progenitors. 31 However, we found that many cells possessing characteristics of neuronal precursors (nestin-and MAP2c-positivity) are also present in these preparations (data not shown). This finding is consistent with other related reports. 16, 32, 33 O-2A cells were maintained in culture for 3 days before being infected with the different vectors (MOI of 1.0) and transferred on a polyornithine substrate in a minimum essential, serum-free Dulbecco's modified Eagle's medium (DMEM) medium, not containing any trophic factor. In culture, O-2A cells form aggregates called 'oligospheres'. 31 Following infection, cells were maintained in this minimum medium for 4 weeks before analysis. This approach allowed testing the residual trophic, proliferative and differentiative capacity of the cells, ensured solely by the NTFs produced by the viral vectors.
Cultures uninfected, infected with the control vector TH-lacZ or with TH-FGF2 did not survive for 4 weeks (Figure 3a ). Based solely on direct observation (since a cell count was precluded by the formation of oligospheres), cultures infected with T0-CNTF/GFP reached an apparently stationary, non proliferating condition (Figure 3b ). In contrast, the vector expressing FGF-2 and CNTF together (TH-FGF2/0-CNTF/GFP) caused proliferation of O-2A progenitors (Figure 3c and d) . Tubular structures were observed departing from the oligospheres. These structures were made of astrocyte offshoots adherent to the substrate (see below), and provided support for migrating cells of bipolar appearance, which could generate other oligospheres by active HSV vector-expressed neurotrophic factors P Marconi et al replication. Alternatively, some of these migrating cells could leave the astrocyte offshoots and adhere to the substrate, developing a bipolar or multipolar, differentiated aspect (Figure 3c and d) .
To determine the differentiation pattern of the cells surviving 4 weeks in the minimum medium, we performed immunocytochemical analysis employing cell-line-specific antibodies: type 2 astrocytes were identified on the basis of expression of glial fibrillary acid protein (GFAP); neurons on microtubule-associated protein-2 (MAP2); oligodendrocytes on 2 0 ,3 0 -cyclic nucleotide-3 0 phosphodiesterase (CNPase). The cells were also checked for the infection of HSV-1-based vectors with the polyclonal antibody anti-HSV (not shown). As described above, control cells and cells infected with either the control vector TH-lacZ or with the FGF-2-expressing vector TH-FGF2 did not survive and, therefore, did not undergo this analysis. Cells surviving after infection with the CNTF-expressing vector T0-CNTF/ GFP differentiated exclusively in astrocytes (data not shown). The vector expressing FGF-2 and CNTF together (TH-FGF2/0-CNTF/GFP) produced a mixed culture containing mostly GFAP-positive cells (presumably astrocytes), but also CNPase-and MAP2-positive cells (presumably oligodendrocytes and neurons) in a significant proportion ( Figure 4 ): based on the average ratio between cells positive for the different markers and the total cell number per field (calculated by counting DAPIpositive nuclei) we estimated more than 70% astrocytes, less than 20% oligodendrocytes and less than 10% neurons.
Transgene expression in vivo
To examine the efficiency and the time-course of transgene expression in vivo, FGF-2 and CNTF gene expression have been studied 3, 15 and 30 days after stereotaxical inoculation of the vectors in the right hippocampus of the rat. FGF-2 is constitutively expressed in several cell populations of the hippocampus, most prominently in CA2 pyramidal neurons and in astrocytes. 34 CNTF is also constitutively expressed in hippocampal neurons (CA1 pyramidal cells) and glia. 35 Therefore, the left, noninjected hippocampus has been employed as an internal control, to allow a precise measurement of the relative increase in gene expression induced by the different vectors.
In keeping with our previous report based on Western blot and in situ hybridization, 30 inoculation of TH-FGF2 or TH-FGF2/0-CNTF/GFP (7 Â 10 5 PFU) induced a significant increase in the number of FGF-2-expressing cells in the area of injection (data not shown). This effect was quite transient, in that it was observed only 3 days, but not 15 or 30 days after vector inoculation. Again, this finding confirms our report. 30 In contrast, inoculation of T0-CNTF/GFP or TH-FGF2/0-CNTF/GFP (7 Â 10 5 PFU) induced a dramatic increase in the number of CNTFexpressing cells in the area of injection ( Figure 5 ). As for FGF-2-overexpressing cells, CNTF-overexpressing cells also displayed nuclear and cytoplasmic positivity to the anti-CNTF antibody. However, the time-course of this effect was less transient, in that it was observed up to 15 days after vector inoculation. At 30 days after inoculation of TH-FGF2, T0-CNTF/GFP or TH-FGF2/0-CNTF/GFP, and at any time-point after inoculation of TH-lacZ, no difference was observed in the pattern of FGF-2 and CNTF expression between the injected and the contralateral hippocampus. Therefore, together with previous reports, 30 these data suggest that inoculation of TH-FGF2/0-CNTF/GFP provides a short-term (1 week) increase in FGF-2 expression accompanied and followed by a longer-lasting (more than 2 weeks) increase in CNTF expression.
In order to evaluate possible toxic effects of the vectors, sections adjacent to those employed for in situ hybridization have been stained with cresyl violet. A small lesion area with surrounding gliosis was observed around the infusion needle tip with all vectors, in keeping with a previous report. 30 However, the lesion area produced by vector inoculation was much smaller than the area displaying transgene overexpression, that is, no sign of cell damage could be observed over the vast majority of the tissue expressing the transgene(s). Furthermore, a certain degree of lesion was also observed in rats injected with saline, indicating the contribution of mechanical factors. (Figure 6a ). At this time, these positive cells were found in the molecular layer of the dentate gyrus (Figures 6b and 7 ), indicating that they were migrating out of the subgranular layer, the site were progenitor cells endowed with mitogenic properties are found in the adult dentate gyrus. These data support the notion that a synergic action takes place between FGF-2 and CNTF to generate proliferation and migration of subgranular progenitor cells in the adult hippocampus.
To determine the differentiation pattern of the TH-FGF2/0-CNTF/GFP-induced proliferating cells, we performed double-label immunocytochemical experiments employing BrdU and cell-line-specific antibodies (GFAP, MAP2 and CNPase). In keeping with the above in vitro data, this vector produced a mix of cell phenotypes, that is, mostly GFAP-positive cells (presumably astrocytes), but also CNPase-and MAP2-positive cells (presumably oligodendrocytes and neurons; Figure 8 ): based on the average ratio between cells positive for the different HSV vector-expressed neurotrophic factors P Marconi et al markers and the total cell number per field (calculated by counting BrdU-positive nuclei), we estimated more than 80% astrocytes, less than 10% oligodendrocytes and less than 10% neurons.
Discussion
The present data extend previous observations that synergies occur between FGF-2 and CNTF; suggest that it will be possible to manipulate CNS cell proliferation, differentiation and migration by using appropriate combinations of NTFs; demonstrate the feasibility of use of HSV-1 vectors for obtaining enduring biological effects in an in vivo system. These main findings will be separately discussed below.
Synergy between FGF-2 and CNTF
Existing evidence clearly indicates that synergies can occur between FGF-2 and CNTF. These data support the notion that these two NTFs, when acting together, promote proliferation and glial differentiation. 8, 18, 21 However, depending on the experimental conditions, the developmental stage and the nervous system region, oligodendroglial 24, 26 and neuronal 22, 23, 25, 27 differentiation have also been reported. It should be noted that these data relate either to peripheral preparations 26 or to CNS in vitro cell systems. 8, 18, [21] [22] [23] [24] [25] 27 Thus, the present one is the first evidence of a synergy between FGF-2 and CNTF occurring in the CNS in vivo.
Not only this is the first evidence of a synergy between FGF-2 and CNTF occurring in the in vivo CNS, but the approach employed in this study is unique compared to all those employed in the above-cited studies, in that it uses viral vectors to transfer the NTF genes. In this respect, the present study provides a proof-of-concept: the viral approach for transferring combinations of NTF to the adult brain is feasible, and can be usefully employed at least in neurobiology research. As stated and described in the Introduction, this approach has several distinct advantages over standard 'pharmacological' studies. With specific reference to functional genomics, advantages include allowing intracrine effects and intracellular processing of the gene product, both precluded with the extracellular application of proteins. In other terms, it is plausible that infected cells will process and deliver (ie target to the proper subcellular domain and secrete at the proper site) the NTF in a much more 'physiological' (or 'physiopathological') way, as compared to simple pharmacological injections.
Identifying how transferred NTFs get to act on hippocampal progenitor cells was behind the scope of this study. The mechanism may be direct, that is, the proliferating cells are those actually infected, or indirect, that is, proliferating cells receive the NTF extrinsically from other, nonprogenitor cells infected by the vector. Based on our data, we can only speculate on this point. Although it is plausible that both mechanisms are taking place, the latter (indirect, NTFs supplied by infected nonprogenitor cells) may predominate. First, as described above, the present data essentially confirm previous 'pharmacological' data, and it is obvious that, under pharmacological conditions, NTF supply is obligatorily 'ab extrinseco'. Second, we observed a large number of infected (transgene-expressing) cells in the injection area, and most of these cells were not located in the position of and/or did not present the morphological features of neural progenitor cells.
Manipulation of CNS cell proliferation, differentiation and migration
The present results demonstrate the possibility of manipulating progenitor cell proliferation, differentiation and migration under normal, homeostatic conditions, that is, when no important drive to proliferation and differentiation is present. Under physiopathological conditions, NTFs and other biological factors are produced (often in a coordinated manner with their receptors) that stimulate the regenerative capacity of endogenous progenitors. 7, 36 Thus, there is optimism about the possibility of augmenting this regenerative capacity by stimulating neural progenitors with appropriate combinations of NTFs. A clear demonstration that this can be the case has been reported by Nakatomi et al. 7 These authors have shown that activation of endogenous progenitors leads to massive regeneration of hippocampal pyramidal neurons after ischemic brain injury, and that intraventricular infusion of NTFs markedly augments the number of newborn neurons. Importantly, these NTF-induced new neurons appear to integrate into the existing brain circuitry and to contribute to ameliorating neurological deficits.
Feasibility of use of HSV-1 vectors for obtaining enduring biological effects in vivo
The present data support the notion that the herpes vector employed may form the basis for the development of other vectors that can be employed in neurobiology studies (and, after further refinement, in gene therapy). First, the vector toxicity seems to be very limited, in keeping with our previous reports. 15, 30 Second, the vector per se does not cause significant inflammation: although a transient infiltration of blood cells at the site of injection was observed, essentially all these cells were polymorphonuclear leukocytes, while very little lymphocytes HSV vector-expressed neurotrophic factors P Marconi et al were found. The presence of polymorphonuclear leukocytes may be related to the mechanical damage. Third, one of the main limitations of HSV-based vectors, namely the relatively short-term transgene expression, does not apply to the present experimental settings. In fact, it is desirable to obtain transient expression of NTFs, because NTFs can trigger plastic changes that will remain detectable when they are no longer expressed, while their long-term expression may be actually detrimental for CNS function. 5 Coherently, we observed a significantly increased number of BrdU-positive cells when the expression of FGF-2 and CNTF was no longer detectably increased.
Another interesting feature of the vectors employed in this study is that it seems possible, by means of different promoters, to obtain different time-courses for the expression of the different NTFs. The present study does not provide a conclusive evidence in this respect, because the differences in the time course of FGF-2 and CNTF expression that we report here may also depend on differences in the sensitivity of the immunohistochemistry for the two gene products. However, modulating the time-course of expression of different NTFs would be important, because, under pathological conditions, the expression patterns of different NTFs varies, albeit always remaining in the short-to medium-term. 37 Thus, appropriate promoters may allow mimicking these different physiopathological patterns of expression.
In conclusion, the present study provides the basis for a new strategy for the repair of brain damage based on the augmentation of the regenerative capacity of NSCs: the use of HSV-based vectors engineered to express multiple NTFs. In the short term, other vectors expressing other combinations of NTF will be prepared and tested: the in vitro systems will allow a first characterization and the selection of the most promising combinations for in vivo analysis; the in vivo analysis will be extended to pathological conditions, such as status epilepticus-and stroke-induced cell damage. The longterm prospect will be the application of this strategy to human therapy. In this respect, it should be mentioned that human trials are underway using an HSV vector expressing proenkephalin for the treatment of pain. 38 The results of this study will be crucial to address issues like safeness and efficacy, that will determine the real potential of HSV vectors for gene therapy.
Materials and methods
Animals
Male Sprague-Dawley rats (280-300 g; Harlan, Italy), were used for all in vivo experiments. Newborn SpragueDawley rat pups (P1-P3), were used for in vitro experiments. Animals were housed under standard conditions: constant temperature (22-241C) and humidity (55-65%), 12 h dark-light cycle, free access to food and water. Procedures involving animals and their care were carried out in accordance with European Community and national laws and policies.
Cell culture and virus stock production
Vero cells (African green monkey kidney cells; ATCC) and Vero-derived cell line, termed 7B, that expresses the HSV-1 immediate-early genes ICP4 and ICP27 required for virus replication 15, 39 were grown in DMEM (EuroClone Ltd) supplemented with glutamine, antibiotics (PSN) and 10% fetal calf serum (FCS); 7B cells were maintained under G418 (1 mg/ml; Sigma) selection. PC12, rat pheochromocytoma cells (ATTC), were maintained in RPMI medium supplemented with 10% FCS. O-2A progenitor cells were maintained in DMEM (Gibco) supplemented with N1 supplement (1 ml/ 100 ml, Sigma), penicillin/streptomycin 2%, L-glutamine (1 ml/100 ml) and biotin (1 mg/100 ml, Sigma). Virus stocks were prepared as previously described, 40 purified on an Optiprep gradient (60% wt/vol iodixanol; Life Technologies), and tested for the absence of replicationcompetent viruses in noncomplementing cell lines.
Plasmid and vector construction Vectors TH-LacZ and TH-FGF2. The control vector TH-LacZ and the FGF-2-expressing vector TH-FGF2 were constructed as previously described. 30 TH-FGF2 contained the sequence of the rat ovarian FGF-2 cDNA (A Baird, The Whittier Institute, La Jolla, CA, USA) placed downstream of the HCMV IE promoter and 5 0 to the polyadenylation sequence from the bovine growth hormone. The control vector, TH-LacZ, contained the Escherichia coli LacZ gene driven by the HCMV IE promoter. All expression cassettes were inserted into the tk locus on a triple deleted recombinant HSV-1 vector lacking three different immediate-early genes (ICP4, ICP27, which are essential for viral replication, and ICP22) using the previously described PacI recombination method. 39 This virus provides low cytotoxicity and high level of transgene expression.
13,30
Vectors T0-CNTF/GFP and TH-FGF2-0-CNTF/GFP.
A plasmid (pB410-CNTF) was constructed by introduction of the rat cntf cDNA (680 pb) from pBluscript-CNTF into the HSV flank sequences of the previously described pB41 plasmid. 14 The cntf cDNA was inserted, under the transcriptional control of the HSV IE ICP0 promoter, into the XbaI sites of the pB41 plasmid, between the two UL41 HSV fragments (HSV genomic positions 90.145-91.631 and 92.230-93.858). 39 pB410-CNTF was then recombined within the genome of the T0-LacZ/GFP viral vector using the previously described Pac-facilitated lacZ substitution method.
39 T0-LacZ/GFP is a replicationdefective HSV-1 viral vector with the backbone of THLacZ (deletion of the three IE ICP4, ICP27 and ICP22), with the cDNA encoding the GFP inserted into the ICP22 locus and with LacZ inserted in the UL41 locus. The production of recombinant viruses was carried out using the standard calcium phosphate transfection procedure with 5 mg of viral DNA and 1 mg of linear pB410-CNTF. Transfection and isolation of the recombinant virus was performed in 7b cells, as previous described. 15, 39 The recombinant virus T0-CNTF/GFP, containing the cntf cDNA, was identified by isolation of a clear plaque phenotype after X-gal staining. This virus was purified by three rounds of limiting dilution and the presence of the transgene was verified by Southern blot analysis. Viral stocks of T0-CNTF/GFP were prepared and titrated using Vero-7b cells. 15 The vector TH-FGF2-0-CNTF/GFP, containing FGF-2 in the tk locus and CNTF in the UL41 locus, was created by genetically crossing the vectors TH-FGF2 and HSV vector-expressed neurotrophic factors P Marconi et al T0-CNTF/GFP. 7b cells, plated in 60 mm Petri dishes, were infected with TH-FGF2 and T0-CNTF/GFP at an MOI of 3.0 and harvested 18 h postinfection. The mixture of viruses derived from the coinfection was titrated, and the viral vector containing both genes was isolated by Southern blot screening. The TH-FGF2-0-CNTF/GFP virus was purified by three rounds of limiting dilution and expression of the transgenes confirmed by Western blot analysis.
Transgene expression in vitro
Vero cells were plated in six-well plates (2 Â 10 5 cells/ well). At 1 day after plating, some wells were infected at an MOI of 1.0 with TH-FGF2, T0-CNTF/GFP, TH-FGF2-0-CNTF/GFP, TH-LacZ or T0-LacZ. At 1-7 days after infection, individual cell monolayers were scraped in Tris-buffered saline (TBS), the cell pellet treated with lysis buffer (0.1 M NaCl, 0.01 M Tris-HCl pH 7.0, 0.001 EDTA pH 8.0, 1% Triton X-100, 1 mg/ml aprotinin, 100 mg/ml PMSF), sonicated and cleared by centrifugation. The presence of FGF-2 and CNTF was determined by Western blot and ELISA.
Western blot analysis. FGF-2 and CNTF protein expression was analyzed in Vero cells (1 Â 10 6 cells) infected at an MOI of 1.0 with the different viruses. Cell extracts, corresponding to 10 mg of total protein, were run onto a 12% SDS-polyacrylamide gel and analyzed by Western blot. The FGF-2 protein was reveled using a mouse anti-human FGF-2 monoclonal antibody (Transduction Laboratories; dilution 1:250) and a mouse antimouse HRP-conjugated secondary antibody (Sigma; dilution 1:4000). Immunocomplexes were detected using the ECL Western blot detection kit (Amersham, Pharmacia Biotech). The CNTF protein was revealed using a chicken anti-rat CNTF polyclonal antibody (Promega; dilution 1:1000) and detected using an anti-chicken IgY, HRP conjugate (Promega; dilution 1:5000) and TMB substrate. Controls were represented by uninfected cells and cells infected with TH-LacZ or T0-LacZ/GFP at an MOI of 1.0.
ELISA. Direct quantification of FGF-2 (R&D System)
and CNTF (Boehringer Mannheim) was determined using an ELISA kit in which 96-well microplates were coated respectively with a monoclonal anti-human FGF-2, which crossreacts with the rat FGF-2, and with a monoclonal anti-rat CNTF (Boehringer Mannheim; dilution 1:40). Briefly, 200 ml of the FGF-2 or CNTF standard and of the supernatants or the clarified lysates from TH-FGF2-, T0-CNTF/GFP-, TH-FGF2-0-CNTF/GFP-, TH-LacZ-or T0-LacZ-infected cells were added to each well, and the plates were incubated for 2 h at room temperature. After washing, 200 ml of peroxidase-conjugate monoclonal anti-human FGF-2 or polyclonal antirat CNTF (Promega; dilution 1:500) were added to each well. Incubation was continued for 2 h at room temperature. After washing, enzymatic activity was detected for FGF-2 by adding the substrate solution for 20 min at room temperature. To detect CNTF, an anti-chicken IgY, HRP conjugate (Promega; dilution 1:1000) and TMB substrate were added. Absorbance values were measured at 450 nm using a microtiter plate spectrophotometer (Titertek Multiskan, Flow Laboratories).
Biological activity in vitro Purification of O-2A cells. Immediately after euthanizing the newborn pups (n ¼ 20) by CO 2 inhalation, meninges-free cerebral hemispheres were removed, transferred in Hank's balanced salt solution (HBSS, Gibco) and washed twice. O-2A cells were obtained using a modification of previously described procedures. 31, 32 Brains were minced and digested in 10 ml HBSS with 0.0025% trypsin/EDTA (Gibco). After 20 min at 371C, 5 ml fetal bovine serum (FBS, to stop trypsin action) and 30 ml HBSS were added and the whole was centrifuged for 10 min at 1500 r.p.m. The supernatant was discarded and the digested tissue was mechanically dissociated by two passages through cell strainers (mesh size 100 and 70 mm). Fresh HBSS was added to help cells through, reaching a final volume of 32 ml. Dissociated cells were layered on preformed Percoll (Sigma) gradients. 33, 41 Percoll is a density gradient material consisting of colloidal silica coated with polyvinylpyrrolidone. Percoll gradients are suitable to sediment the cells in isopycnic banding. Cells are thus separated according to buoyant density. The density of cells and subcellular particles is a function of their water content and is very sensitive to the colloid osmotic pressure, pH and ionic strength. Progenitors are rapidly separated from postmitotic cells using density gradients because their density is higher than that of differentiated cells.
Percoll density gradients were self-generated by centrifuging (14 000 r.p.m., 30 min, 41C) 9 ml Percoll, 1 ml HBSS/10 Â and 10 ml HBSS/1 Â . The cell suspension was then centrifuged at 14 000 r.p.m. for 15 min at 41C. After centrifugation, the material was fractionated in four gross fractions. From the top to the bottom of the tube, the fractions were: (a) a clear supernatant, (b) a white, thin, myelin-like layer, (c) a large, slightly opalescent fraction, and (d) a layer of red blood cells on top of a relatively dense-appearing pellet. Fractions a and b were vacuum aspirated and eliminated. Fraction c consisted of the enriched progenitor fraction. This was carefully pipetted out, harvested and washed by two or more rinses in DMEM (Gibco) supplemented with N1 supplement (1 ml/100 ml, Sigma), penicillin/streptomycin 2%, L-glutamine (1 ml/100 ml) and biotin (1 mg/ 100 ml, Sigma). The purified cell population obtained consisted of O-2A cells in the form of steady, proliferating homotypic aggregates called 'oligospheres'.
Oligosphere induction, maintenance and characterization. The purified cell population was seeded at high cell density (1.5 Â 10 5 cell/cm 2 ) in uncoated plastic tissue culture flasks (T25) and fed with DMEM-N1 (supplemented as described above) and 2% FBS. Flasks were kept at 371C in a humidified 9% CO 2 /91% air atmosphere for 72 h. After elimination of adhering cells, having phenotypes other than precursors, the oligospheres were disaggregated by gentle trituration with a micropipette and the cells were counted in a hemacytometer. The O-2A cells were resuspended in aliquots of 5 Â 10 5 cells and these aliquots were infected with 5 Â 10 5 PFU TH-lacZ, TH-FGF2, T0-CNTF/GFP or TH-FGF2/0-CNTF/GFP recombinant viruses (ie, at an MOI of 1.0). Infected cells were incubated at 371C for 30 min, resuspended in serum-free DMEM, layered (in 100 ml HSV vector-expressed neurotrophic factors P Marconi et al drops) onto glass coverslips precoated with 100 mg/ml polyornithine and laid on the bottom of 12-well tissue culture plates, and allowed to attach for 1 h before adjusting the medium volume to a final 2 ml per well. Finally, cells were cultured in serum-free DMEM without any growth factor (apart from those produced by the vectors) for 4 weeks.
Immunocytochemistry. After the 4-week culture on polyornithine-coated glass, cells were washed with phosphate buffered saline (PBS) 1 Â , fixed with 4% paraformaldehyde in PBS for 20 min and rinsed again with PBS 1 Â . The cells were preincubated with PBS containing 0.15%. Triton X-100 for 5 min, rinsed twice and then blocked in 10% bovine serum albumin (BSA) in PBS for 30 min. Sister coverslips were then incubated for 45 min at room temperature in PBS containing a primary antibody: anti-GFAP (rabbit polyclonal, 1:500 dilution, Sigma), anti-MAP2 (mouse monoclonal, 1:1000 dilution; Sigma) or anti-CNPase (mouse monoclonal 1 mg/ml, Chemicon). Finally, coverslips were washed twice with PBS for 10 min, incubated with TR-conjugated secondary goat anti-mouse antibody (1:250) for 45 min at room temperature, and washed three times with PBS. The last wash contained 10 ng/ml 4 0 ,6-diamidino-2-phenylindole (DAPI, Sigma) in PBS. DAPI was used as a fluorescent counterstain for cell nuclei. Coverslips were mounted using Gel/Mountt (Biomeda).
Transgene expression in vivo HSV infusion in vivo. Under ketamine (100 mg/kg i.p.) anesthesia, a needle connected to a perfusion pump was implanted in the right hippocampus (coordinates: 4.9 mm lateral and 3.6 mm posterior to bregma, 5.0 mm deep from dura). A total of 7 Â 10 5 PFU of vector were injected in a volume of 5 ml at a flow rate of 0.5 ml/min. Animals were killed 3 (n ¼ 12), 15 (n ¼ 16) or 30 (n ¼ 16) days after vector injection. At 3 days after infusion of the vectors, rats of the 15-day and of the 30-day groups were given a single series of four injections of BrdU (50 mg/ kg, i.p., dissolved in propilenic glycol and water, Boehringer Mannheim, Indianapolis, IN, USA) every 2 h during a period of 6 h to label mitotically active cells. Thus, these animals were killed 12 or 27 days after BrdU injections.
FGF-2 and CNTF immunohistochemistry. Rats were killed by decapitation after an anesthetic overdose. Their brains were rapidly removed, immersed in 10% formaline and then paraffin-embedded. Coronal sections (7 mm thick) were cut at the level of the ventral hippocampus (plate 50 42 ) and mounted onto polylysine-coated slides. Sections were dewaxed (two washes in xylol 10 min: 5 min in ethanol 100%, 5 min in ethanol 95%) and then rehydrated in distilled water for 5 min and in PBS 1 Â (PO 4 2À 0.01 M; NaCl 0.15 M) for 10 min. After an incubation in H 2 O 2 3 V for 15 min at room temperature, sections were rapidly rinsed in distilled water and washed again in PBS. They were then incubated with Ultra V Block (Ultra Vision Detection System; Lab Vision Corporation) for 5 min at room temperature, to block nonspecific background staining. After washing in PBS 1 Â for 5 min, sections were incubated overnight at 41C in humid atmosphere with the primary antibody for FGF-2 (10 mg/ml, BD Transduction Laboratories) or for CNTF (5 mg/ml, Santa Cruz Biotechnology). After rinsing in PBS 1 Â , they were incubated with biotinylated goat anti-polyvalent serum (Ultra Vision Detection System; Lab Vision Corporation) at room temperature for 10 min, washed in PBS 1 Â for 5 min and then incubated in streptavidin peroxidase (Ultra Vision Detection System; Lab Vision Corporation) at room temperature for 10 min. The reaction product was detected as a brown substrate using a 10 mg tablet of 3,3-diaminobenzidinetetrahydrochloride (DAB; Sigma) in a solution containing 16.6 ml PBS 1 Â and 130 ml H 2 O 2 24 V. Finally, sections were washed three times in PBS 1 Â (5 min each), counterstained with ematossilin for 2 min and washed again in PBS 1 Â (5 min). Coverslips were mounted using Gel/mountt (Biomeda). The specificity of immunolabeling was verified in all experiments by controls in which the primary antibody was omitted.
Biological activity in vivo BrdU label and double-label immunohistochemistry.
For BrdU immunostaining, DNA was denatured by incubating tissue sections in 2 N HCl for 30 min at 371C and then rinsed three times for 5 min each in PBS 1 Â and treated with H 2 O 2 3 V to block endogenous peroxidase. They were then washed in PBS 1 Â and incubated with Ultra V Block (Ultra Vision Detection System; Lab Vision Corporation) for 5 min at room temperature. Sections were incubated with a primary antibody (diluted in PBS 1 Â ) for BrdU (mouse monoclonal, 1:100; Boehringer Mannheim) overnight at room temperature in a humid atmosphere. After 5 min rinses in PBS, sections were incubated with biotinylated secondary antibody (Ultra Vision Detection System; Lab Vision Corporation) for 10 min, washed again in PBS for 5 min, and then incubated for 10 min in streptavidin peroxidase. After a wash (5 min) in PBS, the reaction product was detected using DAB, as described above. Finally, sections were counterstained with ematossilin for 2 min and the coverslips mounted using Gel/mountt.
For double-labeling, sections were first stained with anti-BrdU antibody and then incubated again with an antibody specific for different cellular markers: anti-MAP2 (mouse monoclonal, 1:1000; Sigma) to label neurons; anti-GFAP (rabbit polyclonal, 1:500; Sigma) to label astrocytes and anti-CNPase (mouse monoclonal, 1 mg/ml; Chemicon) to label oligodendrocytes. The BrdU immunostaining was followed by four washes in PBS 1 Â (5 min each) and an incubation in Ultra V Block (Ultra Vision Detection System; Lab Vision Corporation) for 5 min at room temperature. After a wash in PBS 1 Â for 5 min, sections were incubated with primary antibody (anti-GFAP, anti-MAP2 or anti-CNPase) for 1 h at room temperature in a humid atmosphere. Sections were then rinsed in PBS 1 Â (5 min) and incubated with biotinylated goat anti-polyvalent serum (Ultra Vision Detection System; Lab Vision Corporation) at room temperature for 10 min, washed again in PBS 1 Â for 5 min and incubated in streptavidin peroxidase (Ultra Vision Detection System; Lab Vision Corporation) at room temperature for 10 min. After a wash in PBS 1 Â for 5 min the reaction product was detected using DAB (as above). Sections were counterstained with ematossilin for 2 min and coverslips were mounted as described HSV vector-expressed neurotrophic factors P Marconi et al above. The specificity of immunolabeling was verified in all experiments by controls in which the primary antibody was omitted. It must be noted that the use of very thin (5 mm), paraffin-embedded sections offers the advantages of very high resolution, of clear identification of double-stained cells (in that no overlap of multiple cell layers can occur), and of precise anatomical localization (thanks to the possibility of counterstaining the sections with standard procedures, such as ematossilin).
Quantification and statistical analysis. Quantification of all experiments was performed by two blind investigators, counting the number of BrdU-positive cells in the hilus, the granular and the molecular layer of the ipsilateral (to vector infusion) and of the contralateral dentate gyrus, as well as the cells double-labeled with BrdU and with the markers for neurons, oligodendrocytes, or astrocytes. Six to nine sections per animal have been analyzed in an area encompassing the region where vectors were injected. Statistical analysis has been performed using ANOVA and post hoc the NewmannKeuls test.
